Ann Knoop
research.regionh.dk
0000-0003-2898-1093
The Capital Region of Denmark
126 papers found
Refreshing results…
Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study
Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer
Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer
High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
Machine learning applied in patient-reported outcome research—exploring symptoms in adjuvant treatment of breast cancer
Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world patients
Impact of HER2-low Breast Cancer on Survival in Denmark: A Nationwide Investigation (2007-2019)
Real-world survival of Danish patients with HER2-positive metastatic breast cancer
Identifying recurrent breast cancer patients in national health registries using machine learning
Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis
A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark
A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients
Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study
Interventions supporting cancer patients in making decisions regarding participation in clinical trials - a systematic review
Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
Inter‐observer agreement of tumor infiltrating lymphocytes in primary HER2 ‐positive breast cancer and correlation between tissue microarray and full tumor‐sections
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
HER2-positiv metastatisk brystkræft
[Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly].
Missing publications? Search for publications with a matching author name.